Home

07Feb 2016

The high cost of pharmaceuticals, especially biologics, has become an important issue in the battle to control healthcare costs. In order to overcome this impediment, biosimilar unlike generics were first marketed in Europe in the year 2007. The Affordable Care Act (ACA), which includes the Biologics Price Competition and Innovation Act (BPCIA), defines biosimilar as having […]

18Jan 2016

To most connected with the pharmaceutical industry, it is a common knowledge that the cost of prescription medicine, even traditionally, has always defied the law of gravity. However; what is alarming today is the steep increase in the cost of specialty drugs that target everything from multiple sclerosis to cancer, blood pressure, and even erectile […]